ZNTL News and Press, Zentalis Pharmaceuticals Inc. From 09/01/21

NEW YORK and SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the pu...

The following slide deck was published by Zentalis Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Zentalis Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation

Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles Dosed the first patient in a potentially registrational Phase 2 trial of ZN-c3 in patients with uterine serous carcinoma (USC) Raised approximately $173 mil...

AZEK,AZUL,BIDU,BR,CELH,CSIQ,CYBR,EYE,GDRX,GRWG,IQ,KELYA,MDP,MIDD,MSGS,OGN,PLTR,SDGR,TAL,UTZ,ZNTL For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open

Pacific Biosciences, a San Francisco Bay area company offering long-read sequencing platforms, will acquire Omniome, a San Diego short-read company, for up to $800 million. Shanghai's Zai Lab and Schrödinger of New York formed a global collaboration to develop a novel oncology pr...

NEW YORK and SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that An...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) announces that the first patient has been dosed in the Phase 2 trial of ZN-c3 in adult women with recurrent or persistent uterine serous carcinoma (USC). The trial is an open-label, multicenter study evaluating the clinical activity, safety, pharmacokine...

NEW YORK and SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that th...

SHANGHAI, China, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentera Therapeutics, a clinical-stage biopharmaceutical company with headquarters in Shanghai, China, today announced the successful completion of a $75 million Series B financing. Founding investors OrbiMed Advisors Asia and Tybourne Capi...

BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. Zentalis Pharma, a US-China biopharma, closed a $150 million secondary offering to advance its small molecule cancer portfolio. Shanghai I-Mab announced it has achieved several clin...